# Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

> **NCT05646719** · PHASE3 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 333 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** Phentolamine Opthalmic Solution 0.75%
- **OTHER:** Placebo
- **DRUG:** Low dose pilocarpine
- **OTHER:** Low dose pilocarpine vehicle

## Key facts

- **NCT ID:** NCT05646719
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05646719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05646719, "Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05646719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*